TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
RNAssist collaborates with Fiocruz and Bio-Manguinhos in Brazil on TheraPHIX™, an RNA stabilisation platform that enables liquid-stable mRNA-LNP vaccines effective at ambient temperatures, reducing cold-chain dependency and improving global vaccine access.
RNAssist CEO Andrew Goldsborough will attend the RNA Vaccines and Therapeutics Conference in London, 23–24 September 2025, to share TheraPHIX™, a stabilisation technology enabling RNA vaccines and therapeutics to be stored as liquids at ambient temperatures. Connect with Andrew during the event to discuss your projects and the future of RNA medicines.
A Cell Reports study showcases how vivoPHIX™ enables simultaneous single-cell RNA and phospho-signalling analysis, uncovering dynamic Th17 states with implications for immunology, diagnostics, and beyond.
New protocol from NIAID researchers uses vivoPHIX™ to stabilise RNA at the point of collection — enabling clean, high-quality single-cell sequencing from insect tissues without enzymes, heat, or cold chain.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com